Health-economic impacts of age- and sex-targeted Lassa fever vaccination in endemic regions of Nigeria, Guinea, Liberia and Sierra Leone: a modelling study
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Introduction
Lassa fever is an emerging zoonotic disease endemic to West Africa. Several vaccines aimed at preventing Lassa fever are currently under development, creating a need to assess how best to administer them once licensed for human use.
Methods
We developed a mathematical model using a zoonosis risk map and epidemiological data from recent and ongoing cohort studies to predict the health-economic burden of Lassa fever across age and sex groups in endemic regions. We simulated vaccination campaigns targeting different risk groups to estimate the health-economic benefits of various scenarios for Lassa vaccine administration. Threshold vaccine costs (TVCs) were estimated in International dollars (I$ 2023), accounting for healthcare costs, productivity losses and monetised disability-adjusted life-years (DALYs) averted due to vaccination.
Results
The most efficient strategy for preventing symptomatic Lassa fever was targeting children aged 2-14, for preventing hospitalisation was targeting adolescents and adults aged 15-49, for preventing death was targeting older adults aged 50+, and for preventing DALYs was targeting women of childbearing age (WCBA) aged 15-49. Under base case assumptions, the highest TVC for a single-dose vaccine was estimated at I$7.39 (95% uncertainty interval (UI): I$4.33-I$11.60) when targeting adolescents and adults, followed by I$6.69 (95%UI: I$4.17-I$9.85) when targeting older adults, I$6.10 (95%UI: I$3.56-I$9.74) when targeting WCBA and I$1.94 (95%UI: I$1.10-I$3.10) when targeting children.
Conclusion
These results suggest that the most cost-efficient use of limited doses of Lassa fever vaccine is to target adolescents and adults followed by the elderly.
